Medical News

RSS

Senesco reports on the progress of SNS01-T Phase 1b/2a study for multiple myeloma

Senesco Technologies, Inc. reported today on the progress of its Phase 1b/2a study for the treatment of multiple myeloma, which is the subject of a poster presented today at the 2012 Annual Meeting of the American Society of Clinical Oncology.

5 Jun 2012

Researchers uncover brain signaling pathway responsible for renal excretory function

Boston University School of Medicine (BUSM) researchers recently uncovered a brain signaling pathway responsible for regulating the renal excretion of sodium. The findings appear in the Journal of the Federation of American Societies for Experimental Biology.

5 Jun 2012

Exelixis reports data from cabozantinib phase 3 trial on MTC

Exelixis, Inc. today reported data from the phase 3 pivotal trial of cabozantinib in patients with progressive, unresectable, locally advanced or metastatic medullary thyroid cancer (MTC).

5 Jun 2012

Researchers uncover cellular basis for age-related breast cancer vulnerability

It is well-known that the risks of breast cancer increase dramatically for women over the age of 50, but what takes place at the cellular level to cause this increase has been a mystery. Some answers and the possibility of preventative measures in the future are provided in a new study by researchers at the U.S. Department of Energy (DOE)'s Lawrence Berkeley National Laboratory.

5 Jun 2012

Promising data from Array BioPharma’s MEK162 Phase 2 trial on BRAF and NRAS mutant melanoma

Promising data on MEK162 in an ongoing Phase 2 trial of patients with BRAF and NRAS mutated advanced melanoma was presented today at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois.

5 Jun 2012

Religious practices more successful at promoting certainty about paternity

Religious practices that strongly control female sexuality are more successful at promoting certainty about paternity, according to a study published in the current issue of the Proceedings of the National Academy of Sciences.

5 Jun 2012

OncoGenex announces data from OGX-427 Phase 2 study on mCRPC

OncoGenex Pharmaceuticals, Inc. announced today data from a Phase 2 study of its investigational compound OGX-427 in chemotherapy-naive metastatic castration resistant prostate cancer (mCRPC) patients will be presented during an oral presentation at the 2012 American Society of Clinical Oncology (ASCO) annual meeting on Tuesday, June 5.

5 Jun 2012

Force 3 acquires secureRAD

Force 3, delivering innovative technology solutions, today announced the acquisition of secureRAD, a provider of disruptive technology solutions for the medical imaging industry.

5 Jun 2012

Chatham, Baxter partner to develop and commercialize hemophilia B gene therapy treatment

Baxter International Inc. today announced that it has entered into an exclusive global agreement with Chatham Therapeutics, LLC, an affiliate of Asklepios BioPharmaceutical, Inc. (AskBio), for the development and commercialization of potential treatments for hemophilia B utilizing Chatham's gene therapy technology.

From Baxter International Inc. 5 Jun 2012

Positive results from BioSpecifics’ XIAFLEX Phase III clinical program on Peyronie's disease

BioSpecifics Technologies Corp., a biopharmaceutical company developing first in class collagenase-based products marketed as XIAFLEX in the U.S. and XIAPEX in Europe and Eurasia, today announced positive top-line results from the IMPRESS (The Investigation for Maximal Peyronie's Reduction Efficacy and Safety Studies) Phase III clinical program of XIAFLEX for the treatment of Peyronie's disease, which was conducted by BioSpecifics' partner Auxilium Pharmaceuticals, Inc.

5 Jun 2012

IRadimed receives Novation contract for MRidium MRI Infusion Pump Systems

Novation, the largest health care supply contracting company in the United States, has awarded IRadimed Corporation a three-year single source contract for its MRidium MRI Infusion Pump Systems.

5 Jun 2012

Preliminary results from Incyte’s INCB024360 Phase I trial on solid tumors

Incyte Corporation presented preliminary results today from the ongoing Phase I clinical trial for its oral indoleamine dioxygenase-1 (IDO1) inhibitor, INCB024360, at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

5 Jun 2012

New region on the X chromosome plays a role in migraine

New hope has arrived for migraine sufferers following a Griffith University study with the people of Norfolk Island. Led by Professor Lyn Griffiths from the University's Griffith Health Institute, the team has identified a new region on the X chromosome as playing a role in migraine.

5 Jun 2012

Antisense Pharma presents data from trabedersen Phase I/II cancer study at ASCO 2012

The biopharmaceutical company Antisense Pharma today presents trabedersen complete data from its clinical Phase I/II study in patients with advanced pancreatic cancer, malignant melanoma or colorectal cancer at the international cancer congress ASCO 2012 in Chicago, USA.

5 Jun 2012

Caffeine/coffee intake associated with reduced risk of dementia or delayed onset

Those cups of coffee that you drink every day to keep alert appear to have an extra perk - especially if you're an older adult. A recent study monitoring the memory and thinking processes of people older than 65 found that all those with higher blood caffeine levels avoided the onset of Alzheimer's disease in the two-to-four years of study follow-up. Moreover, coffee appeared to be the major or only source of caffeine for these individuals.

5 Jun 2012

Australian medical researchers hope to block Hendra virus in humans

Australian medical researchers are on the brink of an effective human treatment for the deadly Hendra virus, and potentially the closely related Nipah virus, which has killed more than two hundred people in South East Asia.

5 Jun 2012

Seattle Genetics, Agensys announce interim data from ASG-5ME phase I trial on CRPC

Agensys, Inc., an affiliate of Tokyo-based Astellas Pharma Inc., and Seattle Genetics, Inc. today announced interim data from a phase I clinical trial evaluating ASG-5ME for the treatment of castration-resistant prostate cancer.

5 Jun 2012

New algorithm can help ED physicians to reduce number of heart failure deaths

Physicians can reduce the number of heart failure deaths and unnecessary hospital admissions by using a new computer-based algorithm developed at the Institute for Clinical Evaluative Sciences (ICES) that calculates each patient's individual risk of death. Published in the Annals of Internal Medicine, the algorithm improves upon clinical decision-making and determines whether or not a patient with heart failure should be admitted to hospital.

5 Jun 2012

LifePoint to acquire Woods Memorial Hospital

The Woods Memorial Hospital Board of Directors today announced it has signed an asset purchase agreement for the acquisition of the hospital by LifePoint Hospitals, a leading hospital company focused on providing quality healthcare close to home.

5 Jun 2012

Takeda announces updated results from orteronel phase 2 study on nmCRPC

Millennium: The Takeda Oncology Company with its parent company Takeda Pharmaceutical Company Limited today announced updated results from a phase 2 study of orteronel, a selective oral 17,20 lyase inhibitor, dosed without prednisone in patients with non-metastatic castration resistant prostate cancer (nmCRPC) and rising prostate-specific antigen.

5 Jun 2012

Medical News

Senesco reports on the progress of SNS01-T Phase 1b/2a study for multiple myeloma

Researchers uncover brain signaling pathway responsible for renal excretory function

Exelixis reports data from cabozantinib phase 3 trial on MTC

Researchers uncover cellular basis for age-related breast cancer vulnerability

Promising data from Array BioPharma’s MEK162 Phase 2 trial on BRAF and NRAS mutant melanoma

Religious practices more successful at promoting certainty about paternity

OncoGenex announces data from OGX-427 Phase 2 study on mCRPC

Force 3 acquires secureRAD

Chatham, Baxter partner to develop and commercialize hemophilia B gene therapy treatment

Positive results from BioSpecifics’ XIAFLEX Phase III clinical program on Peyronie's disease

IRadimed receives Novation contract for MRidium MRI Infusion Pump Systems

Preliminary results from Incyte’s INCB024360 Phase I trial on solid tumors

New region on the X chromosome plays a role in migraine

Antisense Pharma presents data from trabedersen Phase I/II cancer study at ASCO 2012

Caffeine/coffee intake associated with reduced risk of dementia or delayed onset

Australian medical researchers hope to block Hendra virus in humans

Seattle Genetics, Agensys announce interim data from ASG-5ME phase I trial on CRPC

New algorithm can help ED physicians to reduce number of heart failure deaths

LifePoint to acquire Woods Memorial Hospital

Takeda announces updated results from orteronel phase 2 study on nmCRPC

How Programmable Nanobiology Could Drive the Fifth Industrial Revolution

Dr. Anthony Grice

Building quality into drug development for safer, faster medicines

Latest News